GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiadis Pharma NV (XAMS:KDS) » Definitions » Gross Margin %

Kiadis Pharma NV (XAMS:KDS) Gross Margin % : 0.00% (As of Dec. 2020)


View and export this data going back to 2015. Start your Free Trial

What is Kiadis Pharma NV Gross Margin %?

Gross Margin % is calculated as gross profit divided by its revenue. Kiadis Pharma NV's Gross Profit for the six months ended in Dec. 2020 was €17.50 Mil. Kiadis Pharma NV's Revenue for the six months ended in Dec. 2020 was €17.50 Mil. Therefore, Kiadis Pharma NV's Gross Margin % for the quarter that ended in Dec. 2020 was 0.00%. If there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.


The historical rank and industry rank for Kiadis Pharma NV's Gross Margin % or its related term are showing as below:


XAMS:KDS's Gross Margin % is not ranked *
in the Biotechnology industry.
Industry Median: 59.43
* Ranked among companies with meaningful Gross Margin % only.

Kiadis Pharma NV had a gross margin of N/A% for the quarter that ended in Dec. 2020 => No sustainable competitive advantage

The 5-Year average Growth Rate of Gross Margin for Kiadis Pharma NV was 0.00% per year.


Kiadis Pharma NV Gross Margin % Historical Data

The historical data trend for Kiadis Pharma NV's Gross Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiadis Pharma NV Gross Margin % Chart

Kiadis Pharma NV Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Gross Margin %
Get a 7-Day Free Trial Premium Member Only - - - - -

Kiadis Pharma NV Semi-Annual Data
Dec12 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20
Gross Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Kiadis Pharma NV's Gross Margin %

For the Biotechnology subindustry, Kiadis Pharma NV's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kiadis Pharma NV's Gross Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiadis Pharma NV's Gross Margin % distribution charts can be found below:

* The bar in red indicates where Kiadis Pharma NV's Gross Margin % falls into.



Kiadis Pharma NV Gross Margin % Calculation

Gross Margin is the percentage of Gross Profit out of sales or Revenue. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

Kiadis Pharma NV's Gross Margin for the fiscal year that ended in Dec. 2020 is calculated as

Gross Margin % (A: Dec. 2020 )=Gross Profit (A: Dec. 2020 ) / Revenue (A: Dec. 2020 )
=17.5 / 17.5
=(Revenue - Cost of Goods Sold) / Revenue
=(17.5 - 0) / 17.5
=N/A %

Kiadis Pharma NV's Gross Margin for the quarter that ended in Dec. 2020 is calculated as


Gross Margin % (Q: Dec. 2020 )=Gross Profit (Q: Dec. 2020 ) / Revenue (Q: Dec. 2020 )
=17.5 / 17.5
=(Revenue - Cost of Goods Sold) / Revenue
=(17.5 - 0) / 17.5
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Kiadis Pharma NV  (XAMS:KDS) Gross Margin % Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Kiadis Pharma NV had a gross margin of N/A% for the quarter that ended in Dec. 2020 => No sustainable competitive advantage


Be Aware

If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.


Kiadis Pharma NV Gross Margin % Related Terms

Thank you for viewing the detailed overview of Kiadis Pharma NV's Gross Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kiadis Pharma NV (XAMS:KDS) Business Description

Traded in Other Exchanges
N/A
Address
Paasheuvelweg 25A, Amsterdam, NLD, 1105 BP
Kiadis Pharma NV is a Netherlands based clinical-stage biopharmaceutical company. It is focused on research, development, and commercialization of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The company's product pipeline includes K-NK002, K-NK003, K-NK00X, and others.

Kiadis Pharma NV (XAMS:KDS) Headlines

No Headlines